UnitedHealth's Oxford Group Picks Praluent As First-Line PCSK9

The battle for US health insurance reimbursement of the roughly $14,000 annual cost of PCSK9 inhibitors continues with Oxford Health Plans, a UnitedHealthcare company, making Praluent (alirocumab) from Regeneron Pharmaceuticals and Sanofi its first choice for lowering LDL cholesterol beyond what's possible with generic statins.